Alnylam Pharmaceuticals - 48 Year Dividend History | ALNY

Historical dividend payout and yield for Alnylam Pharmaceuticals (ALNY) since 1971. The current TTM dividend payout for Alnylam Pharmaceuticals (ALNY) as of April 22, 2019 is $0.00. The current dividend yield for Alnylam Pharmaceuticals as of April 22, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.840B $0.075B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $108.629B 12.24
Gilead Sciences (GILD) United States $78.878B 10.04
Bio-Techne Corp (TECH) United States $7.219B 48.64